Spotlight On... Amgen hits Sandoz with patent infringement suit over Enbrel biosim; Novo, AZ anticipate key trial results; BMS' Opdivo wins new Canadian approval; and more...

Amgen ($AMGN) wants to do everything that it can to protect its top-selling anti-inflammatory drug Enbrel from the advent of biosimilars, and now, it's shoring up its defenses. The company slapped Novartis' ($NVS) Sandoz unit with a patent infringement suit, claiming that Sandoz's Enbrel biosimilar violates a few of its patents for the med. The suit could help Amgen hold on to sales of Enbrel, which brought in $5 billion last year for the company. Read more at FiercePharma

> Novo Nordisk ($NVO) and AstraZeneca ($AZN) each are awaiting results of key clinical trials, with Novo hoping for solid heart results for its diabetes drug Victoza and AZ looking toward results in stroke patients for its blood thinner Brilinta. Report

> Health Canada handed a new approval to Bristol-Myers Squibb's ($BMY) cancer immunotherapy Opdivo, in patients with advanced non-small cell lung cancer. Release

> Another set of women have sued GlaxoSmithKline ($GSK) over birth defects they say are linked to the morning sickness drug Zofran. Report

> Novo Nordisk rolled out the results of a study that suggests its new combination diabetes treatment Xultophy is cost effective compared with other step-up treatments for patients on basal insulin alone. Release

And Finally... Johnson & Johnson ($JNJ) has paired up with LifeScan on blood glucose monitoring. Report

 

Suggested Articles

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?